MetaVia Q2 net loss $4.0M; cash $17.6M; DA-1726 48mg data expected Q4 2025

MetaVia Inc.

2025-Q2 EPS reported -$0.60 vs consensus -$3.48 ▲ beat (+82.7%)

Net loss $4.0M ($0.26/sh) vs $10.1M ($1.85/sh) in Q2 2024; R&D expenses fell to $2.3M from $8.1M.
Cash $17.6M as of June 30, 2025, expected to fund operations into 2026.
Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data due Q4 2025.
Signed AI collaboration with Syntekabio to identify new indications for DA-1241 beyond MASH.
Closed $10.0M private placement in May 2025 with Dong-A ST and Dong-A Socio Holdings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.